Previous 10 | Next 10 |
2023-10-03 08:41:53 ET Gainers: Alx Oncology ( ALXO ) +116% . Vericity ( VERY ) +95% Strengthens Individual Insurance Presence in the United States with the Acquisition of Vericity. POINT Biopharma Global ( PNT ) +85% to acquire Point ...
2023-09-29 20:43:05 ET Renalytix Plc (RNLX) Q4 2023 Earnings Conference Call September 28, 2023 08:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Thomas McLain - President James Sterling - Chief Finan...
2023-09-28 13:19:48 ET More on Renalytix AI Renalytix: Commercializing First AI Kidney Disease Diagnostic Tool Seeking Alpha’s Quant Rating on Renalytix AI Historical earnings data for Renalytix AI Financial information for Renalytix AI For fur...
2023-09-28 12:59:55 ET Gainers: Baudax Bio ( BXRX ) +75% . Chico's Fas ( CHS ) +63% . Aytu BioPharma ( AYTU ) +35% . Axcella Health ( AXLA ) +35% . Vaccinex ( VCNX ) +33% . Organogenesis Holdings ( ORGO ) +27% . F...
2023-09-28 08:24:45 ET More on Ascent Solar Technologies, Cardiff Oncology, etc. Cardiff Oncology (CRDF) Investor Presentation - Slideshow Cardiff Oncology: How The Recommitment Shapes The Investment Thesis (Rating Upgrade) Biggest stock movers today: Cloudflare, Nex...
LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, rep...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...
Renalytix plc (RNLX) is expected to report $-0.13 for Q4 2023
LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live web...
LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease, announces the ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces ...